

Only severe preeclampsia linked to anti-beta-2GP1 immunoglobulin G

January 26 2016



(HealthDay)—Severe preeclampsia (S-PEecl), but not non-severe

preeclampsia (NS-PEecl), is associated with anti β 2GP1 immunoglobulin (Ig)G, according to a study published online Jan. 18 in the *Journal of Thrombosis and Haemostasis*.

Tess Marchetti, from Geneva University Hospitals in Switzerland, and colleagues examined the prevalence of antiphospholipid [antibodies](#) (aPL) in women with previous preeclampsia. Plasma samples were collected six months after delivery for 195 control women, 199 NS-PEecl, and 143 S-PEecl patients. The authors tested plasma for lupus anticoagulant, anticardiolipin (aCL), and anti β 2GP1 antibodies, as well as antibodies against phosphatidylserine/prothrombin complex (aPS/PT) and domain I of the β 2GP1.

The researchers found that after adjustment for confounding variables, there were no significant associations for the NS-PEecl group compared with the control group. Anti β 2GP1 IgG was associated with the S-PEecl group (odds ratio, 16.91), along with age, obesity, smoking, and multiparity. In the three groups there were correlations for anti β 2GP1-domain I IgG with aCL, anti β 2GP1, and aPS/PT IgG. Also in the three groups, aPS/PT IgG correlated with aCL IgG, and aPS/PT IgM correlated with aCL and anti β 2GP1 IgM.

"S-PEecl is a distinct entity from NS-PEecl and is mainly associated with the presence of anti β 2GP1 IgG," the authors write. "Anti β 2GP1 domain I correlate with other aPL IgG tests, and aPS/PT may be promising in patients in which lupus anticoagulant tests cannot be interpreted."

More information: [Abstract](#)
[Full Text \(subscription or payment may be required\)](#)

Copyright © 2016 [HealthDay](#). All rights reserved.

Citation: Only severe preeclampsia linked to anti-beta-2GP1 immunoglobulin G (2016, January 26) retrieved 27 April 2024 from <https://medicalxpress.com/news/2016-01-severe-preeclampsia-linked-anti-beta-2gp1-immunoglobulin.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.